Serum oxytocin profiles in patients with repeated implantation failure during IVF cycles

References

• Ferraretti AP, Goossens V, Kupka M, et al. Assisted reproductive technology in Europe, 2009: results generated from European registers by ESHRE. Hum Reprod. 2013;28:2318–2331.
   PubMed Web of Science ®Google Scholar
• Kushnir VA, Vidali A, Barad DH, et al. The status of public reporting of clinical outcomes in assisted reproductive technology. Fertil Steril. 2013;100:736–741.
   PubMedGoogle Scholar
• Margalioth EJ, Ben-Chetrit A, Gal M, et al. Investigation and treatment of repeated implantation failure following IVF-ET. Hum Reprod. 2006;21:3036–3043.
   PubMed Web of Science ®Google Scholar
• Pierzyński P, Zbucka KM. Uterine contractile activity at embryo transfer – as a new pharmacotherapeutic target in assisted reproduction. Ginekol Pol. 2014;85:609–613.
   PubMed Web of Science ®Google Scholar
• Dittrich R, Mueller A, Oppelt PG, et al. Differences in muscarinic-receptor agonist-, oxytocin-, and prostaglandin-induced uterine contractions. Fertil Steril. 2009;92:1694–1700.
   PubMed Web of Science ®Google Scholar
• Pierzynski P, Reinheimer TM, Kuczynski W. Oxytocin antagonists may improve infertility treatment. Fertil Steril. 2007;88:213.e19–22.
   PubMed Web of Science ®Google Scholar
• Chou PY, Wu MH, Pan HA, et al. Use of an oxytocin antagonist in in vitro fertilization-embryo transfer for women with repeated implantation failure: a retrospective study. Taiwan J Obstet Gynecol. 2011;50:136–140.
   PubMed Web of Science ®Google Scholar
• Liang YL, Kuo TC, Hung KH, et al. Oxytocin antagonist for repeated implantation failure and delay of delivery. Taiwan J Obstet Gynecol. 2009;48:314–316.
   PubMed Web of Science ®Google Scholar
• Lan VT, Khang VN, Nhu GH, et al. Atosiban improves implantation and pregnancy rates in patients with repeated implantation failure. Reprod Biomed Online. 2012;25:254–260.
   PubMed Web of Science ®Google Scholar
• Ng EH, Li RH, Chen L, et al. A randomized double blind comparison of atosiban in patients undergoing IVF treatment. Hum Reprod. 2014;29:2687–2694.
   PubMed Web of Science ®Google Scholar
• Kim SK, Han EJ, Kim SM, et al. Efficacy of oxytocin antagonist infusion in improving in vitro fertilization outcomes on the day of embryo transfer: a meta-analysis. Clin Exp Reprod Med. 2016;43:233–239.
   PubMedGoogle Scholar
• Shim JY, Park YW, Yoon BH, et al. Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG: Int J O&G. 2006;113:1228–1234.
   PubMed Web of Science ®Google Scholar
• Fanchin R, Righini C, Olivennes F, et al. Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization. Hum Reprod. 1998;13:1968–1974.
   PubMed Web of Science ®Google Scholar
• York N, Halbach P, Chiu MA, et al. Oxytocin (OXT)-stimulated inhibition of Kir7.1 activity is through PIP2-dependent Ca2+ response of the oxytocin receptor in the retinal pigment epithelium in vitro. Cell Signal. 2017;37:93–102.
   PubMed Web of Science ®Google Scholar
• Flint AP, Leat WM, Sheldrick EL, et al. Stimulation of phosphoinositide hydrolysis by oxytocin and the mechanism by which oxytocin controls prostaglandin synthesis in the ovine endometrium. Biochem J. 1986;237:797–805.
   PubMed Web of Science ®Google Scholar
• Nanetti L, Raffaelli F, Giulietti A, et al. Oxytocin, its antagonist Atosiban, and preterm labor: a role for placental nitric oxide. J Matern Fetal Neonatal Med. 2015;28:611–616.
   PubMed Web of Science ®Google Scholar
• Huang QY, Rong MH, Lan AH, et al. The impact of atosiban on pregnancy outcomes in women undergoing in vitro fertilization-embryo transfer: a meta-analysis. PLoS One. 2017;12:e0175501.
   PubMed Web of Science ®Google Scholar
• Soloff MS, Fields MJ. Changes in uterine oxytocin receptor concentrations throughout the estrous cycle of the cow. Biol Reprod 1989;40:283–287.
   PubMed Web of Science ®Google Scholar
• Shukovski L, Healy DL, Findlay JK. Circulating immunoreactive oxytocin during the human menstrual cycle comes from the pituitary and is estradiol dependent. J Clin Endocrinol Metab. 1989;68:455–460.
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Matsuda K, Hosokawa K, et al. Expression of G protein-coupled receptor-30, a G protein-coupled membrane estrogen receptor, in oxytocin neurons of the rat paraventricular and supraoptic nuclei. Endocrinology. 2007;148:5842–5850.
   PubMed Web of Science ®Google Scholar
• Xu H, Deng K, Luo Q, et al. High serum FSH is associated with brown oocyte formation and a lower pregnancy rate in human IVF practice. Cell Physiol Biochem. 2016;39:677–684.
   PubMed Web of Science ®Google Scholar
• Aktan E, Bozkurt K, Ozer D, et al. The effect of mid-luteal estradiol level on the outcome of ICSI-ET cycles. Arch Gynecol Obstet. 2004;269:134–138.
   PubMedGoogle Scholar
• Ganesh A, Goswami S, Chattopadhyay R, et al. Luteal phase estradiol level: a potential predictive marker for successful pregnancy in in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2009;91:1018–1022.
   PubMed Web of Science ®Google Scholar
• Friebe-Hoffmann U, Baston DM, Hoffmann TK, et al. The influence of interleukin-1beta on oxytocin signalling in primary cells of human decidua. Regul Pept. 2007;142:78–85.
   PubMedGoogle Scholar
• Kim SH, Pohl O, Chollet A, et al. Differential effects of oxytocin receptor antagonists, atosiban and nolasiban, on oxytocin receptor-mediated signaling in human amnion and myometrium. Mol Pharmacol. 2017;91:403–415.
   PubMed Web of Science ®Google Scholar